Paediatric Prolonged-Release Melatonin has successfully completed a Phase III clinical trial in neurodevelopmental disabled children suffering from sleep disorders. It met the primary efficacy endpoint demonstrating statistically significant improvement in total sleep time (TST) compared to placebo. In addition to TST, secondary efficacy endpoints demonstrating improvements in sleep initiation and maintenance were also met. Safety profile was similar between PedPRM and placebo-treated groups.
Neurim is moving forward with regulatory submissions for this product.

  • Text size: A A A
  • Circadin
  • Recent news

    • Circadin® 2mg (prolonged-release melatonin) is now funded for insomnia in children and adolescents with Neurodevelopmental Disorders in New Zealand
    • Circadin® 2mg (prolonged-release melatonin) is now commercially available in Argentina
    • Neurim Pharmaceuticals Grants Exeltis Marketing Rights for Paediatric Prolonged-Release Melatonin (“PedPRM”) in Spain
  • Partners